Dr Edgardo Santos, speaks to ecancer at the Best of ASCO®️ 2024 Miami Symposium about a talk he presented on antibody drug conjugates (ADCs) in lung cancer.

He begins by explaining the belief that ADCs could replace chemotherapy due to them being less indiscriminate causing fewer toxicities.

Dr Santos then details a number of ADCs that are currently being evaluated in lung cancer including patritumab deruxtecan and Trop-2 inhibitors.